Movement Alert｜BEONE MEDICINES Rises 3.03% in Regular Trading, Global Asset Manager Capital Group Continues Large-Scale Accumulation

Market Focus

昨天

On September 30, BEONE MEDICINES rose 3.03% in regular trading, trading at 224.0 HKD/share, with turnover of HKD 154 million. The rally was driven by continued aggressive buying from The Capital Group Companies, one of the world's largest asset management firms.

According to filings with the Hong Kong Stock Exchange, Capital Group purchased 1.9494 million shares of BEONE MEDICINES on September 24 at an average price of USD 358.77 per share, investing approximately USD 699 million. This followed an earlier purchase on September 9 of 3.0704 million shares at an average price of USD 348.48, totaling roughly USD 1.07 billion. Combined, the two transactions exceed USD 1.7 billion, lifting Capital Group's stake from 6.97% to 8.08%.

The institutional accumulation comes on the heels of strong half-year results, with revenue rising 32.3% year-over-year to USD 3.219 billion and adjusted net profit surging 111% to USD 820 million. The flagship product Brukinsa generated USD 2.342 billion in global sales, accounting for 74% of product revenue. Multiple brokerages maintain a Buy rating, with CLSA naming BEONE MEDICINES as a top pick in China biotech.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1140261443"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1140261443\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1140261443?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-30 10:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1140261443","market":"hk","top_or_hot":-1,"title":"Movement Alert｜BEONE MEDICINES Rises 3.03% in Regular Trading, Global Asset Manager Capital Group Continues Large-Scale Accumulation","media":"Market Focus","content":"<p><p>On September 30, BEONE MEDICINES rose 3.03% in regular trading, trading at 224.0 HKD/share, with turnover of HKD 154 million. The rally was driven by continued aggressive buying from The Capital Group Companies, one of the world's largest asset management firms.</p><p>According to filings with the Hong Kong Stock Exchange, Capital Group purchased 1.9494 million shares of BEONE MEDICINES on September 24 at an average price of USD 358.77 per share, investing approximately USD 699 million. This followed an earlier purchase on September 9 of 3.0704 million shares at an average price of USD 348.48, totaling roughly USD 1.07 billion. Combined, the two transactions exceed USD 1.7 billion, lifting Capital Group's stake from 6.97% to 8.08%.</p><p>The institutional accumulation comes on the heels of strong half-year results, with revenue rising 32.3% year-over-year to USD 3.219 billion and adjusted net profit surging 111% to USD 820 million. The flagship product Brukinsa generated USD 2.342 billion in global sales, accounting for 74% of product revenue. Multiple brokerages maintain a Buy rating, with CLSA naming BEONE MEDICINES as a top pick in China biotech.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜BEONE MEDICINES Rises 3.03% in Regular Trading, Global Asset Manager Capital Group Continues Large-Scale Accumulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜BEONE MEDICINES Rises 3.03% in Regular Trading, Global Asset Manager Capital Group Continues Large-Scale Accumulation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time smaller\">2026-09-30 10:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p><p>On September 30, BEONE MEDICINES rose 3.03% in regular trading, trading at 224.0 HKD/share, with turnover of HKD 154 million. The rally was driven by continued aggressive buying from The Capital Group Companies, one of the world's largest asset management firms.</p><p>According to filings with the Hong Kong Stock Exchange, Capital Group purchased 1.9494 million shares of BEONE MEDICINES on September 24 at an average price of USD 358.77 per share, investing approximately USD 699 million. This followed an earlier purchase on September 9 of 3.0704 million shares at an average price of USD 348.48, totaling roughly USD 1.07 billion. Combined, the two transactions exceed USD 1.7 billion, lifting Capital Group's stake from 6.97% to 8.08%.</p><p>The institutional accumulation comes on the heels of strong half-year results, with revenue rising 32.3% year-over-year to USD 3.219 billion and adjusted net profit surging 111% to USD 820 million. The flagship product Brukinsa generated USD 2.342 billion in global sales, accounting for 74% of product revenue. Multiple brokerages maintain a Buy rating, with CLSA naming BEONE MEDICINES as a top pick in China biotech.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06160","symbol_name":"百濟神州","start_time":0,"source_url":"","article_id":"1140261443","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1140261443","pubTimestamp":1790733941,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On September 30, BEONE MEDICINES rose 3.03% in regular trading, trading at 224.0 HKD/share, with turnover of HKD 154 million. The rally was driven by continued aggressive buying from The Capital...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06160":"百济神州"},"translate_title":"走势预警|BEONE MEDICINES常规交易上涨3.03%，全球资产管理公司资本集团继续大规模累积","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06160":1},"content_text":"On September 30, BEONE MEDICINES rose 3.03% in regular trading, trading at 224.0 HKD/share, with turnover of HKD 154 million. The rally was driven by continued aggressive buying from The Capital Group Companies, one of the world's largest asset management firms.According to filings with the Hong Kong Stock Exchange, Capital Group purchased 1.9494 million shares of BEONE MEDICINES on September 24 at an average price of USD 358.77 per share, investing approximately USD 699 million. This followed an earlier purchase on September 9 of 3.0704 million shares at an average price of USD 348.48, totaling roughly USD 1.07 billion. Combined, the two transactions exceed USD 1.7 billion, lifting Capital Group's stake from 6.97% to 8.08%.The institutional accumulation comes on the heels of strong half-year results, with revenue rising 32.3% year-over-year to USD 3.219 billion and adjusted net profit surging 111% to USD 820 million. The flagship product Brukinsa generated USD 2.342 billion in global sales, accounting for 74% of product revenue. Multiple brokerages maintain a Buy rating, with CLSA naming BEONE MEDICINES as a top pick in China biotech.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}